A health technology assessment based on Chinese guideline: Carbapenems in the treatment of intra-abdominal infection

Objective : To quantitatively assess carbapenems marketed in China in treating intra-abdominal infection, namely, imipenem-cilastatin, meropenem, biapenem and ertapenem, to provide a basis for the selection of carbapenems in hospitals. Methods : In this study, four carbapenems were evaluated by quantitative scoring in five dimensions, including pharmaceutical properties (28 points), efficacy (27 points), safety (25 points), economy (10 points), and other attributes (10 points). Results : The final scores of quantitative assessment for the selection of meropenem, ertapenem and imipenem-cilastatin and biapenem were 74.27, 73.65, 72.40, 69.88 points. Conclusion : Based on the scoring results, meropenem, ertapenem and imipenem-cilastatin can be entered into the medication list of medical institutions as strongly recommended drugs. This study offers guidance on selecting and using carbapenems in hospitals.